ALIT vs NVDA

The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a low Price/Book of 0.39 and a forward P/E of 2.56 suggesting deep value, the company is unprofitable with a staggering -94.23% profit margin and negative ROE of -66.86%. Revenue is declining YoY by 4%, and while recent EPS growth shows a sharp +185.7% YoY increase, this is from a negative base and inconsistent with long-term trends. The stock trades at a steep discount to the $5.07 analyst target, but fundamental deterioration, poor earnings execution (0/4 beats in last 4 quarters), and lack of Altman Z-Score data raise serious sustainability concerns.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.